lymphoma
Conditions
Interventions
Case series:LR-IMED
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. aged 18 to 70 years old; 2. Histopathology confirms CD20 (+) non-GCB subtype diffuse large B-cell lymphoma; 3. Have previously received at least first-line treatment and above and must have received treatment based on the R-CHOP regimen; 4. At least one measurable lesion; 5. Life expectancy >=3 months; 6. Have normal organ function, blood routine liver and kidney function are normal (WBC>=3.5x10^9/L; ANC>=2.0x10^9/L; HGB >100 g/L; PLT >90x10^12/L; ALT, AST <2.5 ULN); 7. No other antitumor treatment; 8. patients can understand and voluntarily participate in this trial can sign informed consent; 9. Female patients of childbearing age have a negative urine pregnancy test before treatment. All enrolled patients must agree to avoid pregnancy or pregnancy during the study period and within 6 months after discontinuation of treatment.
Exclusion criteria
Exclusion criteria: 1. Participated in other clinical trials in the last 3 months; 2. Secondary lymphoma; 3. Transforming lymphoma; 4. Primary central nervous system lymphoma or lymphoma invades central nervous system; 5. Allergic to any research drug; 6. Combined with other malignancies, except for cured basal cell carcinoma; 7. patients with active infections who need treatment; 8. Organ dysfunction such as malignant hypertension, heart failure, dilated cardiomyopathy, unstable angina pectoris, or myocardial infarction occurring within 6 months, renal insufficiency (Cr >1.5 ULN), abnormal liver function (AST / ALT >2.5 ULN or BIL >2.0mg/dl); 9. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Countries
China
Contacts
Public ContactTongyu Lin
Sun Yat-sen University Cancer Center
Outcome results
None listed